Insider · CIK 0001691428
UBS Oncology Impact Fund L.P.
Files at HOWL (Werewolf Therapeutics, Inc.), ITOS (iTeos Therapeutics, Inc.). First filing -, latest -.
In brief
UBS Oncology Impact Fund L.P. files SEC Form 4 as 10% owner at HOWL (Werewolf Therapeutics, Inc.), and also at ITOS (iTeos Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; UBS Oncology Impact Fund L.P. has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 6, 2026 | HOWL Werewolf Therapeutics, Inc. | 80,142 0.16% of outstanding | $27k | Jul 6, 2026 | none |
| Jun 29, 2026 | HOWL Werewolf Therapeutics, Inc. | 87,916 0.18% of outstanding | $28k | Jun 29, 2026 | none |
| May 28, 2026 | HOWL Werewolf Therapeutics, Inc. | 202,029 0.42% of outstanding | $99k | May 28, 2026 | none |
| May 18, 2026 | HOWL Werewolf Therapeutics, Inc. | 240,280 0.49% of outstanding | $124k | May 18, 2026 | none |
| May 11, 2026 | HOWL Werewolf Therapeutics, Inc. | 69,904 0.14% of outstanding | $48k | May 11, 2026 | none |
| May 1, 2026 | HOWL Werewolf Therapeutics, Inc. | 300,821 0.62% of outstanding | $216k | May 1, 2026 | none |
| Apr 29, 2026 | HOWL Werewolf Therapeutics, Inc. | 107,652 0.22% of outstanding | $80k | Apr 29, 2026 | none |
| Apr 27, 2026 | HOWL Werewolf Therapeutics, Inc. | 107,652 0.22% of outstanding | $88k | Apr 27, 2026 | none |
| Jan 6, 2026 | HOWL Werewolf Therapeutics, Inc. | 164,126 0.34% of outstanding | $106k | Jan 6, 2026 | none |
| Dec 29, 2025 | HOWL Werewolf Therapeutics, Inc. | 107,463 0.22% of outstanding | $70k | Dec 29, 2025 | none |
| Dec 22, 2025 | HOWL Werewolf Therapeutics, Inc. | 107,463 0.22% of outstanding | $74k | Dec 22, 2025 | none |
| Dec 10, 2025 | HOWL Werewolf Therapeutics, Inc. | 73,195 0.16% of outstanding | $74k | Dec 10, 2025 | none |
| Dec 3, 2025 | HOWL Werewolf Therapeutics, Inc. | 107,463 0.24% of outstanding | $92k | Dec 3, 2025 | none |
| Nov 24, 2025 | HOWL Werewolf Therapeutics, Inc. | 107,463 0.24% of outstanding | $94k | Nov 24, 2025 | none |
| Nov 17, 2025 | HOWL Werewolf Therapeutics, Inc. | 107,463 0.24% of outstanding | $99k | Nov 17, 2025 | none |
| Nov 10, 2025 | HOWL Werewolf Therapeutics, Inc. | 107,463 0.24% of outstanding | $124k | Nov 10, 2025 | none |
| Nov 4, 2025 | HOWL Werewolf Therapeutics, Inc. | 107,463 0.24% of outstanding | $141k | Nov 4, 2025 | none |
| Oct 30, 2025 | HOWL Werewolf Therapeutics, Inc. | 107,463 0.24% of outstanding | $168k | Oct 30, 2025 | none |
| Oct 27, 2025 | HOWL Werewolf Therapeutics, Inc. | 107,463 0.24% of outstanding | $190k | Oct 27, 2025 | none |
Transactions
Every row this insider has filed, 0 in all, newest first.
Questions about UBS Oncology Impact Fund L.P.
Answered from the filings on this page, as of the latest one.
Is UBS Oncology Impact Fund L.P. buying or selling?
UBS Oncology Impact Fund L.P. has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did UBS Oncology Impact Fund L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and UBS Oncology Impact Fund L.P. has 0.
Where does UBS Oncology Impact Fund L.P. file Form 4?
UBS Oncology Impact Fund L.P. has filed Form 4 at HOWL (Werewolf Therapeutics, Inc.); ITOS (iTeos Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.